Literature DB >> 31385704

Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.

Nenad Manevski1, Lloyd King1, William R Pitt1, Fabien Lecomte1, Francesca Toselli2.   

Abstract

Aldehyde oxidase (AO) catalyzes oxidations of azaheterocycles and aldehydes, amide hydrolysis, and diverse reductions. AO substrates are rare among marketed drugs, and many candidates failed due to poor pharmacokinetics, interspecies differences, and adverse effects. As most issues arise from complex and poorly understood AO biology, an effective solution is to stop or decrease AO metabolism. This perspective focuses on rational drug design approaches to modulate AO-mediated metabolism in drug discovery. AO biological aspects are also covered, as they are complementary to chemical design and important when selecting the experimental system for risk assessment. The authors' recommendation is an early consideration of AO-mediated metabolism supported by computational and in vitro experimental methods but not an automatic avoidance of AO structural flags, many of which are versatile and valuable building blocks. Preferably, consideration of AO-mediated metabolism should be part of the multiparametric drug optimization process, with the goal to improve overall drug-like properties.

Entities:  

Year:  2019        PMID: 31385704     DOI: 10.1021/acs.jmedchem.9b00875

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif.

Authors:  Stephane Perreault; Fatima Arjmand; Jayaraman Chandrasekhar; Jia Hao; Kathleen S Keegan; David Koditek; Eve-Irene Lepist; Clinton K Matson; Mary E McGrath; Leena Patel; Kassandra Sedillo; Joseph Therrien; Nicholas A Till; Adrian Tomkinson; Jennifer Treiberg; Yelena Zherebina; Gary Phillips
Journal:  ACS Med Chem Lett       Date:  2020-04-13       Impact factor: 4.345

2.  Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.

Authors:  Gilles Ouvry; Laurence Clary; Loïc Tomas; Michèle Aurelly; Laetitia Bonnary; Emilie Borde; Claire Bouix-Peter; Laurent Chantalat; Claire Defoin-Platel; Sophie Deret; Mathieu Forissier; Craig S Harris; Tatiana Isabet; Laurent Lamy; Anne-Pascale Luzy; Jonathan Pascau; Catherine Soulet; Alessandro Taddei; Nathalie Taquet; Etienne Thoreau; Emeric Varvier; Emmanuel Vial; Laurent F Hennequin
Journal:  ACS Med Chem Lett       Date:  2019-10-04       Impact factor: 4.345

3.  Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.

Authors:  Frederick W Goldberg; Attilla K T Ting; David Beattie; Gillian M Lamont; Charlene Fallan; M Raymond V Finlay; Beth Williamson; Marianne Schimpl; Alexander R Harmer; Oladipupo B Adeyemi; Pär Nordell; Anna S Cronin; Mercedes Vazquez-Chantada; Derek Barratt; Antonio Ramos-Montoya; Elaine B Cadogan; Barry R Davies
Journal:  ACS Med Chem Lett       Date:  2022-07-07       Impact factor: 4.632

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.

Authors:  Erickson M Paragas; Kanika Choughule; Jeffrey P Jones; John T Barr
Journal:  Methods Mol Biol       Date:  2021

6.  NOX2 inhibitor GSK2795039 metabolite identification towards drug optimization.

Authors:  Elias Carvalho Padilha; Pranav Shah; Ganesha Rai; Xin Xu
Journal:  J Pharm Biomed Anal       Date:  2021-04-26       Impact factor: 3.571

7.  Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.

Authors:  Kei Irie; Atsushi Nakagawa; Hirotoshi Fujita; Ryo Tamura; Masaaki Eto; Hiroaki Ikesue; Nobuyuki Muroi; Keisuke Tomii; Tohru Hashida
Journal:  Clin Transl Sci       Date:  2020-06-29       Impact factor: 4.689

Review 8.  A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors.

Authors:  C S Brian Chia; Weijun Xu; Pearly Shuyi Ng
Journal:  ChemMedChem       Date:  2021-10-28       Impact factor: 3.540

Review 9.  Application of In Vitro Metabolism Activation in High-Throughput Screening.

Authors:  Masato Ooka; Caitlin Lynch; Menghang Xia
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

10.  Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.

Authors:  Laura Goracci; Jenny Desantis; Aurora Valeri; Beatrice Castellani; Michela Eleuteri; Gabriele Cruciani
Journal:  J Med Chem       Date:  2020-10-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.